Dudediligence.

X4 Pharmaceuticals, Inc

XFORNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$560,000Sep ’24$1.4MDec ’24$28.8MMar ’25$2.0MJun ’25$1.8MSep ’25$2.6MDec ’25$2.7MMar ’26$8.8MJun ’26
Net income, by quarter
−$36.7MSep ’24−$39.8MDec ’24$282,000Mar ’25−$25.7MJun ’25−$29.8MSep ’25−$23.9MDec ’25−$20.2MMar ’26−$16.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$0.00$0.00$2.6M$35.1M
Gross profitnone on file$0.00$0.00$1.8M$29.4M
Operating income−$85.1M−$87.6M−$107.5M−$36.4M−$86.9M
Net income−$88.7M−$93.9M−$101.2M−$37.5M−$79.2M
Operating cash flow−$70.9M−$77.1M−$96.5M−$130.9M−$85.6M
Free cash flow−$71.5M−$77.2M−$96.6M−$131.2M−$85.6M
Cash$81.8M$121.7M$99.2M$55.7M$217.0M
Debt$33.3M$33.8M$55.0M$75.0M$75.0M
Shares outstanding28.1M121.7M167.4M5.7M90.9M